DE602005020269D1 - Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren - Google Patents

Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren

Info

Publication number
DE602005020269D1
DE602005020269D1 DE602005020269T DE602005020269T DE602005020269D1 DE 602005020269 D1 DE602005020269 D1 DE 602005020269D1 DE 602005020269 T DE602005020269 T DE 602005020269T DE 602005020269 T DE602005020269 T DE 602005020269T DE 602005020269 D1 DE602005020269 D1 DE 602005020269D1
Authority
DE
Germany
Prior art keywords
treprostinil
treatment
footpromments
derivative
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005020269T
Other languages
German (de)
English (en)
Inventor
Michael Wade
Roger Andrew Jeffs
Deborah Strootman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of DE602005020269D1 publication Critical patent/DE602005020269D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DE602005020269T 2004-04-12 2005-04-12 Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren Expired - Lifetime DE602005020269D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56115704P 2004-04-12 2004-04-12
PCT/US2005/012471 WO2005099680A2 (en) 2004-04-12 2005-04-12 Use of treprostinil to treat neuropathic diabetic foot ulcers

Publications (1)

Publication Number Publication Date
DE602005020269D1 true DE602005020269D1 (de) 2010-05-12

Family

ID=34965914

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005020269T Expired - Lifetime DE602005020269D1 (de) 2004-04-12 2005-04-12 Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren

Country Status (10)

Country Link
US (2) US7879909B2 (https=)
EP (1) EP1744739B1 (https=)
JP (1) JP2007532663A (https=)
KR (1) KR101186029B1 (https=)
CN (1) CN101287457B (https=)
AT (1) ATE462427T1 (https=)
CA (1) CA2562614C (https=)
DE (1) DE602005020269D1 (https=)
ES (1) ES2340939T3 (https=)
WO (1) WO2005099680A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1917866B (zh) * 2003-12-16 2010-12-15 联合治疗公司 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途
ATE462427T1 (de) * 2004-04-12 2010-04-15 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
CA2698721A1 (en) 2007-09-07 2009-03-12 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
KR20160048222A (ko) 2007-12-17 2016-05-03 유나이티드 세러퓨틱스 코오포레이션 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법
RU2358757C1 (ru) * 2008-03-11 2009-06-20 Федеральное государственное образовательное учреждение высшего профессионального образования "Чувашский государственный университет им. И.Н. Ульянова" Способ лечения длительно незаживающих ран у больных сахарным диабетом
US8350079B2 (en) * 2008-05-08 2013-01-08 United Therapeutics Corporation Treprostinil formulation
JP5649645B2 (ja) * 2009-05-07 2015-01-07 ユナイテッド セラピューティクス コーポレイション プロスタサイクリンアナログの固形製剤
EP3108888B1 (en) 2010-03-15 2020-02-12 United Therapeutics Corporation Treatment for pulmonary hypertension
WO2011153363A1 (en) 2010-06-03 2011-12-08 United Therapeutics Corporation Treprostinil production
EP2681204B1 (en) 2011-03-02 2016-04-27 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
EP2970091A4 (en) 2013-03-14 2017-02-08 United Therapeutics Corporation Solid forms of treprostinil
US20140275616A1 (en) 2013-03-15 2014-09-18 United Therapeutics Corporation Salts of treprostinil
EP2978313B1 (en) 2013-03-25 2018-02-21 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
LT3060041T (lt) 2013-10-25 2021-03-25 Insmed Incorporated Prostaciklino junginiai
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
CN106573066A (zh) 2014-06-13 2017-04-19 联合治疗学有限公司 曲前列环素制剂
ES2778274T3 (es) 2014-10-20 2020-08-10 United Therapeutics Corp Síntesis de productos intermedios para producir derivados de prostaciclina
JP6866043B2 (ja) 2014-11-18 2021-04-28 インスメッド インコーポレイテッド トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法
IL252577B (en) 2014-12-03 2022-07-01 Steadymed Ltd Preservative-free treprostinil formulations and methods and devices for use with same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
ES2972423T3 (es) 2015-07-28 2024-06-12 Lilly Co Eli Preparado farmacéutico para mejorar la absorción y la acción hipoglucemiante postprandial de la insulina
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US10898494B2 (en) 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
JP7220650B2 (ja) 2016-09-26 2023-02-10 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
US20190290597A1 (en) * 2016-12-05 2019-09-26 Corsair Pharma, Inc. Dermal and transdermal administration of treprostinil and salts thereof
AU2019344541B2 (en) 2018-09-18 2022-01-06 Eli Lilly And Company Erbumine salt of treprostinil
ES2980934T3 (es) * 2019-01-22 2024-10-03 Akribes Biomedical Gmbh Modificadores selectivos del receptor de glucocorticoides para tratar la cicatrización alterada de heridas en la piel
JP7455144B2 (ja) 2019-04-29 2024-03-25 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
AU2021255621A1 (en) 2020-04-17 2022-10-20 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
JP7608480B2 (ja) 2020-06-09 2025-01-06 ユナイテッド セラピューティクス コーポレイション トレプロスチニルのフマリルジケトピペリジンプロドラッグ
WO2022132655A1 (en) 2020-12-14 2022-06-23 United Therapeutics Corporation Methods of treating disease with treprostinil prodrugs
AU2022229367A1 (en) 2021-03-03 2023-09-14 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
US20230263807A1 (en) 2022-02-08 2023-08-24 United Therapeutics Corporation Treprostinil iloprost combination therapy
KR20250002687A (ko) 2022-04-29 2025-01-07 자오커 파마슈티컬 (광저우) 컴퍼니., 리미티드 트레프로스티닐 소프트 미스트 흡입제
JP2026503509A (ja) 2023-01-18 2026-01-29 ユナイテッド セラピューティクス コーポレイション 肺動脈性肺高血圧症の治療
AU2024208919A1 (en) 2023-01-19 2025-07-17 United Therapeutics Corporation Treprostinil analogs
DE102023104616B4 (de) 2023-02-24 2025-03-27 Heinz Kurz Gmbh Chirurgische Schneidevorrichtung für die Otologie und Verfahren zu deren Betrieb
DE202023100902U1 (de) 2023-02-24 2023-03-09 Heinz Kurz Gmbh Chirurgische Schneidevorrichtung für die Otologie
US20250049743A1 (en) 2023-08-08 2025-02-13 United Therapeutics Corporation Method of producing an oral osmotic pharmaceutical delivery system and a pharmaceutical batch produced using the same
WO2026035705A1 (en) 2024-08-06 2026-02-12 United Therapeutics Corporation Treating pulmonary hypertension based on novel biomarker

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490537A (en) * 1977-04-19 1984-12-25 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
US4306075A (en) * 1980-03-28 1981-12-15 The Upjohn Company Composition and process
US4486598A (en) 1982-02-22 1984-12-04 The Upjohn Company Carbacyclin analogs
DE3315356A1 (de) * 1982-04-30 1983-11-17 Ono Pharmaceutical Co. Ltd., Osaka Verwendung von prostaglandinanalogen
CA1241324A (en) 1984-03-08 1988-08-30 Paul A. Aristoff Interphenylene carbacyclin derivatives
JPH0680027B2 (ja) * 1985-09-18 1994-10-12 財団法人相模中央化学研究所 プロスタサイクリン類及びこれらを含有する薬剤
US4837342A (en) * 1986-02-28 1989-06-06 Sagami Chemical Research Center Prostacyclin analogue, and blood circulation improving agent and anti-ulcer composition containing it as active ingredient
US5663203A (en) * 1986-09-11 1997-09-02 Schering Aktiengesellschaft Agents containing prostacyclin derivatives for topical application
US4730078A (en) * 1987-05-13 1988-03-08 G. D. Searle & Co. Allenic prostacyclins
GB8814438D0 (en) * 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
GB9011588D0 (en) * 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
DE4135193C1 (https=) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
US6171786B1 (en) * 1992-09-17 2001-01-09 Board Of Trustees Of University Of Illinois Methods for preventing multidrug resistance in cancer cells
WO1994017806A1 (fr) * 1993-02-03 1994-08-18 Teijin Limited Composition de preparation dermatologique contenant de la prostacycline comme principe actif
US6451815B1 (en) * 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
EP1045695B1 (en) * 1997-11-14 2004-03-24 United Therapeutics Corporation Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f 1? to treat peripheral vascular disease
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
JP2002540203A (ja) 1999-03-29 2002-11-26 ニューロゲン コーポレイション Ｎｋ−３および／またはｇａｂａ（ａ）受容体リガンドとしての４−置換キノリン誘導体
US6700025B2 (en) 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
AU2002339730A1 (en) * 2002-08-28 2004-03-19 Universita "Campus Bio-Medico" Di Roma Use of prostacyclin and analogs thereof for improving venous flow
CN101265226B (zh) 2003-05-22 2013-04-24 联合治疗公司 化合物和释放前列环素类似物的方法
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
CN1917866B (zh) 2003-12-16 2010-12-15 联合治疗公司 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途
CA2549801C (en) 2003-12-16 2012-10-16 United Therapeutics Corporation Use of treprostinil to improve kidney functions
ATE462427T1 (de) 2004-04-12 2010-04-15 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
CN101495122B (zh) 2006-05-15 2011-10-05 联合治疗公司 使用定量吸入器给予曲前列尼
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
CA2678258A1 (en) 2007-02-09 2008-08-14 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
KR20160048222A (ko) 2007-12-17 2016-05-03 유나이티드 세러퓨틱스 코오포레이션 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법
JP5649645B2 (ja) 2009-05-07 2015-01-07 ユナイテッド セラピューティクス コーポレイション プロスタサイクリンアナログの固形製剤

Also Published As

Publication number Publication date
US7879909B2 (en) 2011-02-01
WO2005099680A2 (en) 2005-10-27
KR101186029B1 (ko) 2012-09-27
US20110092599A1 (en) 2011-04-21
CN101287457A (zh) 2008-10-15
ES2340939T3 (es) 2010-06-11
KR20070007887A (ko) 2007-01-16
CA2562614A1 (en) 2005-10-27
US8563614B2 (en) 2013-10-22
CA2562614C (en) 2013-09-17
US20050282903A1 (en) 2005-12-22
WO2005099680A3 (en) 2005-12-01
JP2007532663A (ja) 2007-11-15
EP1744739A2 (en) 2007-01-24
CN101287457B (zh) 2011-11-16
ATE462427T1 (de) 2010-04-15
EP1744739B1 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
DE602005020269D1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
ATE473736T1 (de) Verwendung von treprostinil zur behandlung von ischämischen läsionen
ATE441418T1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
EA200802213A1 (ru) Способы лечения заболеваний крови
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
MX2007006397A (es) Derivados de tetrahidropirano.
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
ATE245416T1 (de) Neue fettanaloge zur behandlung von diabetes
UA88491C2 (ru) Способ очищения транс-(-)-δ9-тетрагидроканабинола и транс-(+)-δ9-тетрагидроканабинола (варианты)
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DK1755634T3 (da) Oligopeptider til formindskelse af forhöjet blodurinstofkoncentration
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
NO20076405L (no) Anvendelse av 24-nor-UDCA
NO20055741L (no) Nye kjemiske forbindelser
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
WO2006114105A8 (en) Use of modified factor vii for treating bleeding
BRPI0507886A (pt) método de purificação de albumina compreendendo uma etapa de nanofiltração, solução e composição para uso terapêutico contendo-o
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
ATE496913T1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
SE0301947D0 (sv) New method and uses
EA200701584A1 (ru) Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения

Legal Events

Date Code Title Description
8364 No opposition during term of opposition